FDA drug shortages · status interpretation
A “resolved” entry in the FDA Drug Shortage Database describes a national supply assessment for a specific drug and presentation. It does not guarantee that every pharmacy, hospital or wholesaler has immediate stock.
What a status change can establish
FDA maintains records for current and resolved shortages and discontinuations. The agency says manufacturers provide most shortage information, while FDA works with manufacturers to prevent or reduce supply disruptions. A database status therefore reflects FDA’s national-level record, not a live inventory feed from every point in the distribution chain.
A responsible report identifies the active ingredient, dosage form, strength, package or presentation, manufacturer entry, status wording and retrieval time. A status for one presentation should not be extended to another strength, container or manufacturer without checking its separate record.
Why local availability may lag
Product can move through manufacturing, allocation, wholesale and local ordering systems at different speeds. FDA itself notes that a medicine being out of stock is often temporary and localized. A recently resolved national shortage may therefore coexist with a local backorder, while a locally available item does not disprove a national shortage affecting other presentations.
Federal status answers what FDA reports nationally for the named presentation. Local stock answers what a particular dispenser can supply at a stated time. Neither layer substitutes for the other.
A verification card for editors
- Open the live FDA database entry and record the retrieval timestamp.
- Copy the exact generic name, dosage form, strength and presentation.
- Separate each manufacturer’s status and reason language.
- Ask a local source only about its own inventory and ordering horizon.
- Avoid promising availability or recommending a clinical substitute.
What patients can verify next
Patients can ask a pharmacist whether the exact prescribed presentation is available and ask the prescribing clinician how to handle an access problem. The newsroom cannot determine whether another product is appropriate, and a shortage-status article should never tell someone to change, split, delay or stop treatment.